DOI: 10.36347/sjmcr.2015.v03i05.031

Pages: 451-453

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, are known to play a significant role in EGFR mutation positive non-small cell lung cancer. We report long progression-free survival with first-line Erlotinib an EGFR mutation NSCLC. The present study reports the case of an 83-year-old female never smoker was diagnosed with EGFR NSCLC deletions in exon 19 after bone biopsy following pathologic fracture of the right femur. The patient received Erlotinib after palliative femoral radiotherapy. Currently, the patient is stable, with no evidence of disease progression after 36 months of treatment with Erlotinib. We describe the disease and the treatment safety using Erlotinib in the elderly patient.